LIPELLA PHARMACEUTICALS INC.【LIPO】

時価総額

$78.2万

PER

既存ジェネリック薬の処方改良による新薬開発の新興企業。LP-10やLP-310などの処方改良治療薬を展開。2024年にシリーズBで約590万ドルを調達。米国（ピッツバーグ）を拠点に研究開発、従業員7人（2025年3月26日）。

	2022年 12月31日	2023年 12月31日	2024年 12月31日
Cash and cash equivalents	5	3	2
Grants receivable	113,655	32,286	84,713
Prepaid expenses	563,891	103,256	347,676
Total Current Assets	6	3	3
Furniture, fixtures and equipment	-	140,294	140,294
Furniture, fixtures and equipment (Accumulated Depreciation)	-	127,544	130,430
Furniture and fixtures, net	-	12,750	9,864
Operating lease right of use asset	150,821	135,144	46,754
Total Assets	6	4	3
Accounts payable	384,357	138,016	388,191
Accrued expenses	389,209	77,280	237,886
Operating lease liability	58,262	89,223	47,605
Payroll liability	67,832	80,836	80,735
Total Current Liabilities	1	385,355	754,417
Operating lease liability, net of current portion	96,258	47,371	-
Total Liabilities	1	432,726	754,417
Preferred stock, $0.0001 par value; 20,000,000 shares authorized; 25,975 shares Series B and 303,041 shares Series C issued and outstanding at December 31, 2024, -0- shares issued and outstanding at December 31, 2023	-	-	33
Common stock, $0.0001 par value; 200,000,000 shares authorized, 1,208,919 shares issued and outstanding at December 31, 2024 and 756,743 shares issued and outstanding at December 31, 2023	574	605	121
Additional paid-in capital	10	13	17
Accumulated deficit	-5,704,878	-10,323,843	-15,340,107
Total stockholders' equity	5	3	2
Total liabilities and stockholders' equity	6	4	3